APGE
NASDAQ
US
Apogee Therapeutics, Inc. - Common Stock
$84.34
▲ +$0.10
(+0.12%)
Vol 677K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$5.2B
ROE
-39.1%
D/E
0.00
Beta
0.79
52W
$26–$81
Wall Street Consensus
23 analysts · Apr 202610
Strong Buy
9
Buy
4
Hold
0
Sell
0
Strong Sell
82.6%
Buy Rating
Price Chart
Similar Stocks
CAI
Caris Life Sciences Inc
$7.6B
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10.6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70.7
$3.2B
IMVT
Immunovant Inc
$5.1B
DNTH
Dianthus Therapeutics Inc
$1.8B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17.3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
About Apogee Therapeutics, Inc. - Common Stock
На жаль, не маю інформації про компанію APGE з галузі Biotechnology. Можливо, назва компанії вказана невірно, або це приватна компанія, дані про яку не є загальнодоступними. Щоб надати релевантну інформацію, уточніть назву компанії або надайте додаткові відомості про її діяльність.
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $-1.12
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-1.12 | — | — |
| Dec 2025 | $-1.08 | $-1.03 | +$0.05 |
| Sep 2025 | $-1.21 | $-1.11 | +$0.10 |
| Jun 2025 | $-1.10 | $-1.13 | $-0.03 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -34.6% | -34.6% | -34.6% | -34.6% | -39.1% | -39.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 16.36 | 16.36 | 16.36 | 16.36 | 15.86 | 15.86 |
Key Ratios
ROA (TTM)
-36.9%
P/B
3.7
EPS (TTM)
$-4.36
52W High
$80.99
52W Low
$26.20
$26.20
52-Week Range
$80.99
How does APGE compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
APGE valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
3.7
▲
50%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
APGE profitability vs Biotechnology peers
ROE
-39.1%
▲
42%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-36.9%
▲
21%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
APGE financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
15.9
▲
257%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.8
▼
19%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
APGE fundamentals radar
APGE
Peer median
Industry
APGE profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio